Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced its financial results and operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025.
The company reported a fourth quarter sequential and year-on-year revenue growth of 16%, driven by increased demand for drug testing cartridges.
Fiscal 2025 marked a year of growth for the company, propelled by higher-margin cartridge sales, operational streamlining, and regulatory advancements supporting future U.S. market expansion beyond Forensic Use Only settings.
Revenue Growth
Reported 16% revenue growth in the fourth quarter compared to the previous year, attributed to increased demand for drug testing cartridges.
International Expansion
Expanded commercial presence globally with customers in 24 countries and 18 distribution partners.
Strategic Priorities for Fiscal 2026
Focused on accelerating growth, advancing operational excellence, and expanding into the U.S. market beyond Forensic Use Only settings.
- The company's efforts to secure U.S. FDA 510(k) clearance for market expansion beyond Forensic Use Only settings showcase strategic progress.
- Higher-margin cartridge sales and operational efficiency improvements contributed to the company's revenue growth in fiscal 2025.
Intelligent Bio Solutions remains committed to driving global growth, achieving FDA clearance to enter the U.S. market, and providing reliable testing solutions to organizations worldwide.